Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
431 stopped studies mapped to Urinary System Carcinoma and descendants · 87% state a reason
Over the 431 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01806064 | Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal… | Phase 1 / Phase 2 | terminated | Mar 7, 2013 | Tracon Pharmaceuticals Inc. | The study did not meet endpoint. | Other (stated, no rule matched) |
| NCT03719300 | Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC | Phase 2 | terminated | Oct 25, 2018 | Anchiano Therapeutics Israel Ltd. | Lack of efficacy | Efficacy / futility |
| NCT03598816 | PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for…(PIVOT-RCC) | Phase 2 | withdrawn | Jul 26, 2018 | Washington University School of Medicine | FDA Contingencies unresolved | Other (stated, no rule matched) |
| NCT04260360 | Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma | Phase 1 | withdrawn | Feb 7, 2020 | NanOlogy, LLC | Not initiated | Other (stated, no rule matched) |
| NCT03167151 | Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)(PemBla) | Phase 1 / Phase 2 | terminated | May 25, 2017 | University of Oxford | The study failed to recruit within the permitted timeframe | Enrollment / accrual |
| NCT02688348 | Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients… | N/A | withdrawn | Feb 23, 2016 | Jonsson Comprehensive Cancer Center | not stated | Not stated |
| NCT02212730 | A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell… | Phase 1 | terminated | Aug 8, 2014 | Merck Sharp & Dohme LLC | Terminated early due to low enrollment | Enrollment / accrual |
| NCT03407976 | Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies(APPEASE) | Phase 1 | terminated | Jan 23, 2018 | University of Utah | Funding source withdrew financial support prior to start of Phase II portion of study | Funding |
| NCT02169284 | Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery | Phase 2 | terminated | Jun 23, 2014 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02170389 | Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer | N/A | terminated | Jun 23, 2014 | Roswell Park Cancer Institute | sponsor having financial difficulties | Funding |
| NCT00953446 | Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of… | N/A | terminated | Aug 6, 2009 | Beth Israel Deaconess Medical Center | not stated | Not stated |
| NCT02089334 | Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal… | Phase 1 / Phase 2 | terminated | Mar 17, 2014 | Rexahn Pharmaceuticals, Inc. | not stated | Not stated |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid… | Phase 1 | terminated | Nov 17, 2017 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT02837991 | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell… | Phase 1 | terminated | Jul 20, 2016 | Celldex Therapeutics | Development of CDX-014 discontinued | Other (stated, no rule matched) |
| NCT03517995 | Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention | Phase 2 | withdrawn | May 8, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Grant not approved | Other (stated, no rule matched) |
| NCT03927248 | PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer | Phase 1 / Phase 2 | withdrawn | Apr 25, 2019 | HealthPartners Institute | funding issues | Funding |
| NCT03335059 | Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced…(RITE-USA) | Phase 3 | terminated | Nov 7, 2017 | Medical Enterprises Ltd. | poor enrollment | Enrollment / accrual |
| NCT00854022 | Genetic Susceptibility to Kidney Cancer | — | terminated | Mar 2, 2009 | Baylor College of Medicine | Funding ended | Funding |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | Phase 2 | terminated | Jul 12, 2011 | Cambridge University Hospitals NHS Foundation Trust | Following DMC review, due to slow recruitment of evaluable patients. | Enrollment / accrual |
| NCT03943771 | Effect on Pre-operative Anxiety of a Personalized Three-dimensional Kidney Model Prior to…(R3DP-A) | N/A | withdrawn | May 9, 2019 | University Hospital, Bordeaux | Schedule issue | Other (stated, no rule matched) |
| NCT03935347 | Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating… | Phase 2 | withdrawn | May 2, 2019 | Roswell Park Cancer Institute | no accrual | Enrollment / accrual |
| NCT03692338 | INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or…(INTERVAL) | N/A | terminated | Oct 2, 2018 | Duke University | Poor accrual | Enrollment / accrual |
| NCT00975806 | Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy… | Phase 1 / Phase 2 | terminated | Sep 11, 2009 | Celgene | MTD determined sub-optimal as efficacious treatment for renal cell carcinoma. | Other (stated, no rule matched) |
| NCT00670748 | Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer | Phase 2 | terminated | May 2, 2008 | National Cancer Institute (NCI) | A more highly selected protocol with ESO TCR opened for pts with melanoma | Other (stated, no rule matched) |
| NCT02795819 | Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer | Phase 1 | terminated | Jun 10, 2016 | Virginia Commonwealth University | Study drug no longer being clinically developed by manufacturer | Drug supply |
| NCT01239342 | Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer | Phase 2 | terminated | Nov 11, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01545817 | Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma(CATChEz) | Phase 2 | terminated | Mar 7, 2012 | Novartis Pharmaceuticals | As the therapeutic landscape in renal cell carcinoma is changing, it has become apparent that… | Other (stated, no rule matched) |
| NCT02447887 | Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma… | Phase 1 / Phase 2 | terminated | May 19, 2015 | Fox Chase Cancer Center | IRB study closure facilitated by Investigator | Investigator |
| NCT01599754 | Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients(ATLAS) | Phase 3 | terminated | May 16, 2012 | SFJ Pharma Ltd. II | Primary endpoint did not reach statistical significance | Other (stated, no rule matched) |
| NCT03408561 | Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer | N/A | withdrawn | Jan 24, 2018 | University of Southern California | No accrual | Enrollment / accrual |
| NCT00323076 | [18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal… | Phase 1 / Phase 2 | terminated | May 9, 2006 | AHS Cancer Control Alberta | Retirement of former Qualified Investigator and lack of resources to complete study. | Investigator |
| NCT01611662 | Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle… | Phase 2 | terminated | Jun 5, 2012 | Fox Chase Cancer Center | Extreme Toxicity | Safety / toxicity |
| NCT01391130 | A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma | Phase 2 | terminated | Jul 11, 2011 | Eli Lilly and Company | Study Terminated due to Insufficient Efficacy | Efficacy / futility |
| NCT02952989 | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | Phase 1 | terminated | Nov 2, 2016 | Seagen Inc. | Due to overall benefit/risk profile | Other (stated, no rule matched) |
| NCT03111901 | Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer(UVA-AM-002) | Phase 1 / Phase 2 | withdrawn | Apr 13, 2017 | William Grosh, MD | funding was withdrawn | Funding |
| NCT00538772 | An Exploratory Correlative Study of Biomarkers in Patients With Metastatic Renal Cell… | — | withdrawn | Oct 3, 2007 | Kim Chi | not stated | Not stated |
| NCT02494635 | Ultrasound and Biomarker Tests in Predicting Cancer Aggressiveness in Tissue Samples of… | — | terminated | Jul 10, 2015 | University of Southern California | The PI left institution | Investigator |
| NCT02428335 | Study of Muscle Energy Metabolism in RCC Patients Treated With Sunitinib | — | withdrawn | Apr 28, 2015 | AHS Cancer Control Alberta | Insufficient financial resources to conduct research and complete trial. | Funding |
| NCT03528057 | Evaluation of Hemostatic Agents in Robotic-assisted Laparoscopic Partial Nephrectomy | N/A | withdrawn | May 17, 2018 | Northwestern University | Difficulty recruiting participants. | Enrollment / accrual |
| NCT02005614 | A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI… | N/A | terminated | Dec 9, 2013 | Yale University | Unable to recruit patients. | Enrollment / accrual |
| NCT03185182 | Diagnostic Imaging for Clear Cell Renal Cell Carcinoma(RCCSCAN) | Phase 2 | terminated | Jun 14, 2017 | Region Skane | Due to "early stopping rule" as defined in the study protocol | Other (stated, no rule matched) |
| NCT02202044 | Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After… | N/A | terminated | Jul 28, 2014 | University of Colorado, Denver | The institution was requiring extensive changes to the protocol | Other (stated, no rule matched) |
| NCT01195649 | Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or… | — | terminated | Sep 6, 2010 | Bayer | not stated | Not stated |
| NCT03029832 | A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in… | Phase 2 | terminated | Jan 24, 2017 | Genentech, Inc. | The study was prematurely terminated due to slow patient accrual and discontinuation of clinical… | Enrollment / accrual |
| NCT00727532 | Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | N/A | terminated | Aug 4, 2008 | Northwestern University | Low Accrual | Enrollment / accrual |
| NCT02699853 | Robotic or Open Radical Cystectomy in Treating Patients With Bladder Cancer | N/A | terminated | Mar 4, 2016 | University of Southern California | PI decided to revamp the protocol completely and will submit as new study. | Other (stated, no rule matched) |
| NCT03399643 | A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable…(Announce) | — | terminated | Jan 16, 2018 | Hoffmann-La Roche | Tecentriq label restriction for first line limited the patient population and scientific question… | Other (stated, no rule matched) |
| NCT02438852 | Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in… | Phase 3 | withdrawn | May 8, 2015 | University of Southern California | No funding | Funding |
| NCT01198158 | Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer… | Phase 3 | terminated | Sep 9, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02867332 | PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma. | Phase 1 | withdrawn | Aug 15, 2016 | Peking University | No funding | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Oct 19, 2020source: clinicaltrials